CSL 112

Drug Profile

CSL 112

Alternative Names: Apolipoprotein A-I - CSL Behring; CSL-112; CSL112 (reconstituted HDL) - CSL; rHDL - CSL

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator CSL
  • Class Antihyperlipidaemics; Cardiovascular therapies; Lipoproteins
  • Mechanism of Action Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atherosclerosis; Myocardial infarction

Most Recent Events

  • 01 Aug 2016 CSL Behring initiates a phase II trial for Myocardial infarction in USA, Hungary and Germany (IV) (NCT02742103)
  • 13 Apr 2016 CSL Behring plans a phase II trial for Myocardial infarction in USA (IV) (NCT02742103)
  • 01 Mar 2016 CSL completes a phase II trial in Acute myocardial infarction in USA, United Kingdom, Australia, Austria, Bulgaria, Canada, Czech Republic, Denmark, France, Israel, Italy, Hungary, Spain, Germany, Netherlands and Poland (NCT02108262)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top